We combined cell-free ribosome display and cell-based yeast display selection to build specific protein binders to the extracellular domain of the human interleukin 9 receptor alpha (IL-9Rα). The target, IL-9Rα, is the receptor involved in the signalling pathway of IL-9, a pro-inflammatory cytokine medically important for its involvement in respiratory diseases. The successive use of modified protocols of ribosome and yeast displays allowed us to combine their strengths-the virtually infinite selection power of ribosome display and the production of (mostly) properly folded and soluble proteins in yeast display. The described experimental protocol is optimized to produce binders highly specific to the target, including selectivity to common proteins such as BSA, and proteins potentially competing for the binder such as receptors of other cytokines. The binders were trained from DNA libraries of two protein scaffolds called 57aBi and 57bBi developed in our laboratory. We show that the described unconventional combination of ribosome and yeast displays is effective in developing selective small protein binders to the medically relevant molecular target.

Institute of Biotechnology of the Czech Academy of Sciences Vestec Czech Republic

Zobrazit více v PubMed

Nuttall SD & Walsh RB (2008) Display scaffolds: protein engineering for novel therapeutics. Curr Opin Pharmacol 8, 609-615.

Stiel AC, Feldmeier K & Hocker B (2014) Identification of protein scaffolds for enzyme design using scaffold selection. Methods Mol Biol 1216, 183-196.

Miao Z, Levi J & Cheng Z (2011) Protein scaffold-based molecular probes for cancer molecular imaging. Amino Acids 41, 1037-1047.

Weidle UH, Auer J, Brinkmann U, Georges G & Tiefenthaler G (2013) The emerging role of new protein scaffold-based agents for treatment of cancer. Cancer Genomics Proteomics 10, 155-168.

Rothe C & Skerra A (2018) Anticalin((R)) proteins as therapeutic agents in human diseases. BioDrugs 32, 233-243.

Samanta A, Aziz AA, Jhingan M, Singh SR, Khanani AM & Chhablani J (2020) Emerging therapies in neovascular age-related macular degeneration in 2020. Asia Pac J Ophthalmol (Phila) 9, 250-259.

Deuschle FC, Ilyukhina E & Skerra A (2021) Anticalin(R) proteins: from bench to bedside. Expert Opin Biol Ther 21, 509-518.

Gille H, Hulsmeyer M, Trentmann S, Matschiner G, Christian HJ, Meyer T, Amirkhosravi A, Audoly LP, Hohlbaum AM & Skerra A (2016) Functional characterization of a VEGF-A-targeting anticalin, prototype of a novel therapeutic human protein class. Angiogenesis 19, 79-94.

Gebauer M & Skerra A (2020) Engineered protein scaffolds as next-generation therapeutics. Annu Rev Pharmacol Toxicol 60, 391-415.

Pluckthun A (2012) Ribosome display: a perspective. Methods Mol Biol 805, 3-28.

Boder ET & Wittrup KD (1997) Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 15, 553-557.

Pham PN, Huliciak M, Biedermannova L, Cerny J, Charnavets T, Fuertes G, Herynek S, Kolarova L, Kolenko P, Pavlicek J et al. (2021) Protein binder (ProBi) as a new class of structurally robust non-antibody protein scaffold for directed evolution. Viruses 13, 190.

Kolarova L, Zahradnik J, Huliciak M, Mikulecky P, Peleg Y, Shemesh M, Schreiber G & Schneider B (2022) De novo developed protein binders mimicking interferon lambda signaling. FEBS J 289, 2672-2684.

Benczik M & Gaffen SL (2004) The interleukin (IL)-2 family cytokines: survival and proliferation signaling pathways in T lymphocytes. Immunol Invest 33, 109-142.

Shimbara A, Christodoulopoulos P, Soussi-Gounni A, Olivenstein R, Nakamura Y, Levitt RC, Nicolaides NC, Holroyd KJ, Tsicopoulos A, Lafitte JJ et al. (2000) IL-9 and its receptor in allergic and nonallergic lung disease: increased expression in asthma. J Allergy Clin Immunol 105, 108-115.

Horejsi Z, Stach L, Flower TG, Joshi D, Flynn H, Skehel JM, O'Reilly NJ, Ogrodowicz RW, Smerdon SJ & Boulton SJ (2014) Phosphorylation-dependent PIH1D1 interactions define substrate specificity of the R2TP cochaperone complex. Cell Rep 7, 19-26.

Vorup-Jensen T, Ostermeier C, Shimaoka M, Hommel U & Springer TA (2003) Structure and allosteric regulation of the alpha X beta 2 integrin I domain. Proc Natl Acad Sci USA 100, 1873-1878.

Lebl M (1999) Solid-phase synthesis of combinatorial libraries. Curr Opin Drug Discov Devel 2, 385-395.

Zahnd C, Amstutz P & Pluckthun A (2007) Ribosome display: selecting and evolving proteins in vitro that specifically bind to a target. Nat Methods 4, 269-279.

Mouratou B, Behar G, Paillard-Laurance L, Colinet S & Pecorari F (2012) Ribosome display for the selection of Sac7d scaffolds. Methods Mol Biol 805, 315-331.

Okda F, Liu X, Singrey A, Clement T, Nelson J, Christopher-Hennings J, Nelson EA & Lawson S (2015) Development of an indirect ELISA, blocking ELISA, fluorescent microsphere immunoassay and fluorescent focus neutralization assay for serologic evaluation of exposure to North American strains of porcine epidemic diarrhea virus. BMC Vet Res 11, 180.

Nolo R, Herbrich S, Rao A, Zweidler-McKay P, Kannan S & Gopalakrishnan V (2017) Targeting P-selectin blocks neuroblastoma growth. Oncotarget 8, 86657-86670.

Baldauf KJ, Salazar-Gonzalez RA, Doll MA, Pierce WM Jr, States JC & Hein DW (2020) Role of human N-acetyltransferase 2 genetic polymorphism on aromatic amine carcinogen-induced DNA damage and mutagenicity in a Chinese hamster ovary cell mutation assay. Environ Mol Mutagen 61, 235-245.

Haycock JW (1993) Polyvinylpyrrolidone as a blocking agent in immunochemical studies. Anal Biochem 208, 397-399.

Rothe A, Nathanielsz A, Hosse RJ, Oberhauser F, Strandmann EP, Engert A, Hudson PJ & Power BE (2007) Selection of human anti-CD28 scFvs from a T-NHL related scFv library using ribosome display. J Biotechnol 130, 448-454.

Sun Y, Ning B, Liu M, Gao X, Fan X, Liu J & Gao Z (2012) Selection of diethylstilbestrol-specific single-chain antibodies from a non-immunized mouse ribosome display library. PLoS One 7, e33186.

Kabir ME, Krishnaswamy S, Miyamoto M, Furuichi Y & Komiyama T (2009) An improved phage-display panning method to produce an HM-1 killer toxin anti-idiotypic antibody. BMC Biotechnol 9, 99.

Mehdipour T, Tohidkia MR, Ata Saei A, Kazemi A, Khajeh S, Rahim Rahimi AA, Nikfarjam S, Farhadi M, Halimi M, Soleimani R et al. (2020) Tailoring subtractive cell biopanning to identify diffuse gastric adenocarcinoma-associated antigens via human scFv antibodies. Immunology 159, 96-108.

Uyttenhove C, Druez C, Renauld JC, Hérin M, Noël H & Van Snick J (1991) Autonomous growth and tumorigenicity induced by P40/interleukin 9 cDNA transfection of a mouse P40-dependent T cell line. J Exp Med 173, 519-522.

Mikulecky P, Zahradnik J, Kolenko P, Cerny J, Charnavets T, Kolarova L, Necasova I, Pham PN & Schneider B (2016) Crystal structure of human interferon-gamma receptor 2 reveals the structural basis for receptor specificity. Acta Crystallogr D 72, 1017-1025.

Aricescu AR, Lu W & Jones EY (2006) A time- and cost-efficient system for high-level protein production in mammalian cells. Acta Crystallogr D 62, 1243-1250.

Blaha J, Pachl P, Novak P & Vanek O (2015) Expression and purification of soluble and stable ectodomain of natural killer cell receptor LLT1 through high-density transfection of suspension adapted HEK293S GnTI(−) cells. Protein Expr Purif 109, 7-13.

Backliwal G, Hildinger M, Kuettel I, Delegrange F, Hacker DL & Wurm FM (2008) Valproic acid: a viable alternative to sodium butyrate for enhancing protein expression in mammalian cell cultures. Biotechnol Bioeng 101, 182-189.

Regulation of IL-24/IL-20R2 complex formation using photocaged tyrosines and UV light